Skip to main content
NIH funding notice RFA-AI-20-078

Immune Development in Early Life (IDEaL) (U19 Clinical Trial Not Allowed)

Closed on June 18, 2021.

Posted
January 12, 2021
Close date
June 18, 2021
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $3,355,876 in first-year total cost, median $1,677,938.

Most frequent study sections

  1. Special Emphasis Panel[ZAI1 MMF-X (J1)]2

Most frequent institutions

  1. BOSTON CHILDREN'S HOSPITAL1
  2. RESEARCH INST NATIONWIDE CHILDREN'S HOSP1
Competing awards under RFA-AI-20-078 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2022Early life respiratory viral infections shape immune development trajectories1U19AI168632-01PASCUAL, MARIA VIRGINIARAMILO, OCTAVIORESEARCH INST NATIONWIDE CHILDREN'S HOSP, OH$1,689,999ZAI1
2022Immune development in early life (IDEAL) shapes vaccine response, respiratory infectious diseaseand asthma1U19AI168643-01LEVY, OFERBOSTON CHILDREN'S HOSPITAL, MA$1,665,877ZAI1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.